Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.49 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334272 | 0.98 | HRH4 (0.47) | HRH4CAMKK2HRH3ADORA2AAURKA | |
| SCHEMBL28317093 | 0.96 | HRH4 (0.44) | HRH4CAMKK2HRH3ADORA2AAURKA | |
| SCHEMBL2036795 | 0.92 | ADORA2A (0.45) | HRH4CAMKK2HRH3ADORA2AAURKA | |
| Hydrochloric Acid SCHEMBL2018276 | 0.90 | ADORA2A (0.44) | HRH4CAMKK2HRH3ADORA2AAURKA | |
| SCHEMBL1334584 | 0.83 | ADORA2A (0.40) | HRH4CAMKK2HRH3ADORA2AAURKA | |
| SCHEMBL31226997 | 0.83 | CDK1 (0.47) | CAMKK2HRH3ADORA2AAURKAHSP90AA1 | |
| SCHEMBL20292302 | 0.83 | HRH4 (0.57) | HRH4HRH3ADORA2AAURKAHSP90AA1 | |
| SCHEMBL1334581 | 0.83 | ADORA2A (0.40) | HRH4CAMKK2HRH3ADORA2AAURKA | |
| SCHEMBL2571086 | 0.83 | PIK3CD (0.50) | HRH3ADORA2AAURKAHSP90AA1PRKACA | |
| SCHEMBL31227542 | 0.82 | MAPK14 (0.44) | CAMKK2HRH3ADORA2AAURKAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546148-A1 | THERAPEUTIC COMPOUNDS BASED ON PYRAZOLOPYRIDINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004033454-A1 | THERAPEUTIC COMPOUNDS BASED ON PYRAZOLOPYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-22 | — | — | WO | claimed |
| EP-1401836-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF HERPES VIRAL INFECTIONS | SmithKline Beecham Corporation (US) | 2004-03-31 | — | — | EP | claimed |
| EP-1372643-A1 | PYRAZOLOPYRIDINES, PROCESS FOR THEIR PREPARATION AND USE AS THERAPEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2003000689-A1 | IMIDAZO`1,2-A!PYRIDINE DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF HERPES VIRAL INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2002078700-A1 | PYRALOPYRIDINES, PROCESS FOR THEIR PREPARATION AND USE AS THERAPTEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| CN-114751909-B | Preparation method of rebaudinib intermediate | 杭州福斯特药业有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-114751909-A | Preparation method of Ribociclib intermediate | 杭州福斯特药业有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20110039873-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY | MEDICINOVA, INC. | 2011-02-17 | — | — | US | disclosed |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
| EP-1546148-A1 | THERAPEUTIC COMPOUNDS BASED ON PYRAZOLOPYRIDINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1485385-A1 | PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SmithKline Beecham Corporation (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004033454-A1 | THERAPEUTIC COMPOUNDS BASED ON PYRAZOLOPYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-1366048-A2 | PYRAZOLOPYRIDINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2003076441-A1 | PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003000689-A1 | IMIDAZO`1,2-A!PYRIDINE DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF HERPES VIRAL INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002088124-A2 | PYRAZOLO'1,5-A!PYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002083672-A1 | ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002078700-A1 | PYRALOPYRIDINES, PROCESS FOR THEIR PREPARATION AND USE AS THERAPTEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002072581-A2 | PYRAZOLOPYRIADINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039873-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY | PARK7, MAPKAPK5, MAPK1 | HRH4 3772/4885CAMKK2 207/4885HRH3 4137/4885 |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | HRH4 1/4885CAMKK2 2744/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.